血小板活化因子乙酰水解酶基因多态性与脓毒症易感性的相关性研究
|
摘要
目的：
脓毒症是危重患者主要死亡原因之一,给临床治疗带来严峻挑战。近些年来,研究表明,血小板活化因子乙酰水解酶(PAF acetylhydrolases, PAF-AH,又称为PLA2G7)能够特异性降解重要促炎因子——血小板活化因子(Platelet activating factor, PAF),在脓毒症中具有潜在的保护作用。PAF-AH基因单核苷酸多态性可能影响其酶的活性,与多种炎症性疾病及其预后相关。目前国内外PAF-AH基因多态性与脓毒症是否相关的报道不多。本实验采用分子生物学方法对脓毒症患者PAF-AH基因Ala379Val和Val279Phe位点基因多态性进行分析,探讨其多态性与脓毒症易感性及预后的关系。
方法：
1、标本收集：脓毒症组来源于2008年10月至2009年8月天津两家3级甲等医院收治的脓毒症患者66例。依据诊断标准将入选的脓毒症患者分成普通脓毒症组和严重脓毒症组；根据住院28天转归的不同分为生存组和死亡组。对照组来自门诊健康体检人群,共68例。
2、采用PCR-RFLP技术,扩增PAF-AH基因的第11和第9外显子,然后分别应用限制性内切酶Fnu4hⅠ、AclⅠ消化PCR产物,通过电泳酶切图谱直接判断碱基的变异,进行SNP基因分型。同时对含有等位基因多态性的片段进行DNA测序。分析66例不同程度的脓毒症患者及68名健康对照者PAF-AH基因Ala379Val、Val279Phe位点的多态性,用统计学方法计算SNP的基因型及等位基因的分布频率。
结果：
1、PAF-AH基因Ala379Val位点3种基因型中,脓毒症组66例中仅1例纯合子Val/Val型,19例杂合子Val/Ala型,46例纯合子Ala/Ala型；对照组68例中2例Val/Val型,22例Val/Ala型,44例Ala/Ala型。Ala379Val基因型及等位基因频率分布在对照组和脓毒症组之间、在普通脓毒症组和严重脓毒症组及对照组之间、在存活组和死亡组及对照组之间尚无统计学意义。
2、PAF-AH基因Val279Phe位点3种基因型中,脓毒症组66例中全部为纯合子Val/Val型,对照组68例中仅1例纯合子Phe/Phe型,其余全部为纯合子Val/Val型,均未发现杂合子Val/Phe型。Val279Phe基因型及等位基因频率分布在对照组和脓毒症组之间、在普通脓毒症组和严重脓毒症组及对照组之间、在存活组和死亡组及对照组之间尚无统计学意义。
结论：
PAF-AH基因Ala379Val、Val279Phe位点多态性与脓毒症易感性、预后及病情严重程度可能无明显相关。
Objective:
Sepsis was one of the leading causes of death in critically ill patients; pose serious challenges to the clinical treatment. In recent years, studies had shown that platelet activating factor acetylhydrolase (PAF acetylhydrolases, PAF-AH, also known as PLA2G7) to specific degradation of platelet activating factor which was an important pro-inflammatory cytokines. In septic disease PAF-AH had a potentially protective effect. PAF-AH gene single nucleotide polymorphisms could affect its enzyme activity, with a variety of inflammatory disease and its prognosis. However, currently the relation of sepsis and PAF-AH gene polymorphism was not clarified in domestic and abroad. In this study we used molecular biology methods to analysis PAF-AH gene Ala379Val and Val279Phe polymorphisms in patients with sepsis and explored the relations between polymorphisms and sepsis susceptibility and prognosis.
Methods:
1. Specimen collection:66 patients of sepsis group were selected from October 2008 to August 2009 in Tianjin two Third Grade Class hospitals admitted with sepsis. Based on diagnostic criteria of sepsis patients were divided into mild group and severe sepsis group; according to 28-day turn-over patients were divided into survival group and death group.68 cases of control group come from the healthy out-patient medical groups.
2. By PCR-RFLP technique, PAF-AH gene exon 11 and 9 was amplified. Then PCR products were separately digested by restriction endonuclease Fnu4h I and Acl I. SNP variation and genotyping were directly determined by gel electrophoresis patterns. At the same time, PCR products containing allele gene polymorphism were sent to sequence analysis. PAF-AH gene Ala379Val and Val279Phe polymorphisms were analyzed in 66 cases of varying degrees of sepsis patients and 68 healthy controls. Then SNP genotype and allele frequency distribution were computed.
Results:
1. All the samples of the PAF-AH gene in the Val379Ala site had three kinds of genotypes:in 66 cases of sepsis group there were 1 homozygous Val/Val type, 19 heterozygous Val/Ala type,46 homozygous Ala/Ala type; in 68 cases of control group there were 2 Val/Val type,22 Val/Ala type,44 Ala/Ala type. The Val379Ala genotypic distribution and allele gene frequency in the patients with sepsis was not significantly different from those in the healthy controls; no statistically significant difference was observed among the survival group、the death group and the control group; no statistically significant difference was observed among the mild sepsis group, severe sepsis group and control group.
2. PAF-AH gene of Val279Phe polymorphism could have three kinds of genotypes:All 66 patients in the sepsis group were the homozygous Val/Val type; control group 68 cases, only one case was homozygous Phe/Phe type, and the others were homozygous Val/Val type, not found heterozygous Val/Phe type. The Val279Phe genotypic distribution and allele gene frequency in the patients with sepsis was not significantly different from those in the healthy controls; no statistically significant difference was observed among the survival group、the death group and the control group; no statistically significant difference was observed among the mild sepsis group, severe sepsis group and control group.
Conclusion:
No associations were found between PAF-AH gene Val379Ala and Val279Phe polymorphisms and sepsis susceptibility, prognosis and severity.
脓毒症是危重患者主要死亡原因之一,给临床治疗带来严峻挑战。近些年来,研究表明,血小板活化因子乙酰水解酶(PAF acetylhydrolases, PAF-AH,又称为PLA2G7)能够特异性降解重要促炎因子——血小板活化因子(Platelet activating factor, PAF),在脓毒症中具有潜在的保护作用。PAF-AH基因单核苷酸多态性可能影响其酶的活性,与多种炎症性疾病及其预后相关。目前国内外PAF-AH基因多态性与脓毒症是否相关的报道不多。本实验采用分子生物学方法对脓毒症患者PAF-AH基因Ala379Val和Val279Phe位点基因多态性进行分析,探讨其多态性与脓毒症易感性及预后的关系。
方法：
1、标本收集：脓毒症组来源于2008年10月至2009年8月天津两家3级甲等医院收治的脓毒症患者66例。依据诊断标准将入选的脓毒症患者分成普通脓毒症组和严重脓毒症组；根据住院28天转归的不同分为生存组和死亡组。对照组来自门诊健康体检人群,共68例。
2、采用PCR-RFLP技术,扩增PAF-AH基因的第11和第9外显子,然后分别应用限制性内切酶Fnu4hⅠ、AclⅠ消化PCR产物,通过电泳酶切图谱直接判断碱基的变异,进行SNP基因分型。同时对含有等位基因多态性的片段进行DNA测序。分析66例不同程度的脓毒症患者及68名健康对照者PAF-AH基因Ala379Val、Val279Phe位点的多态性,用统计学方法计算SNP的基因型及等位基因的分布频率。
结果：
1、PAF-AH基因Ala379Val位点3种基因型中,脓毒症组66例中仅1例纯合子Val/Val型,19例杂合子Val/Ala型,46例纯合子Ala/Ala型；对照组68例中2例Val/Val型,22例Val/Ala型,44例Ala/Ala型。Ala379Val基因型及等位基因频率分布在对照组和脓毒症组之间、在普通脓毒症组和严重脓毒症组及对照组之间、在存活组和死亡组及对照组之间尚无统计学意义。
2、PAF-AH基因Val279Phe位点3种基因型中,脓毒症组66例中全部为纯合子Val/Val型,对照组68例中仅1例纯合子Phe/Phe型,其余全部为纯合子Val/Val型,均未发现杂合子Val/Phe型。Val279Phe基因型及等位基因频率分布在对照组和脓毒症组之间、在普通脓毒症组和严重脓毒症组及对照组之间、在存活组和死亡组及对照组之间尚无统计学意义。
结论：
PAF-AH基因Ala379Val、Val279Phe位点多态性与脓毒症易感性、预后及病情严重程度可能无明显相关。
Objective:
Sepsis was one of the leading causes of death in critically ill patients; pose serious challenges to the clinical treatment. In recent years, studies had shown that platelet activating factor acetylhydrolase (PAF acetylhydrolases, PAF-AH, also known as PLA2G7) to specific degradation of platelet activating factor which was an important pro-inflammatory cytokines. In septic disease PAF-AH had a potentially protective effect. PAF-AH gene single nucleotide polymorphisms could affect its enzyme activity, with a variety of inflammatory disease and its prognosis. However, currently the relation of sepsis and PAF-AH gene polymorphism was not clarified in domestic and abroad. In this study we used molecular biology methods to analysis PAF-AH gene Ala379Val and Val279Phe polymorphisms in patients with sepsis and explored the relations between polymorphisms and sepsis susceptibility and prognosis.
Methods:
1. Specimen collection:66 patients of sepsis group were selected from October 2008 to August 2009 in Tianjin two Third Grade Class hospitals admitted with sepsis. Based on diagnostic criteria of sepsis patients were divided into mild group and severe sepsis group; according to 28-day turn-over patients were divided into survival group and death group.68 cases of control group come from the healthy out-patient medical groups.
2. By PCR-RFLP technique, PAF-AH gene exon 11 and 9 was amplified. Then PCR products were separately digested by restriction endonuclease Fnu4h I and Acl I. SNP variation and genotyping were directly determined by gel electrophoresis patterns. At the same time, PCR products containing allele gene polymorphism were sent to sequence analysis. PAF-AH gene Ala379Val and Val279Phe polymorphisms were analyzed in 66 cases of varying degrees of sepsis patients and 68 healthy controls. Then SNP genotype and allele frequency distribution were computed.
Results:
1. All the samples of the PAF-AH gene in the Val379Ala site had three kinds of genotypes:in 66 cases of sepsis group there were 1 homozygous Val/Val type, 19 heterozygous Val/Ala type,46 homozygous Ala/Ala type; in 68 cases of control group there were 2 Val/Val type,22 Val/Ala type,44 Ala/Ala type. The Val379Ala genotypic distribution and allele gene frequency in the patients with sepsis was not significantly different from those in the healthy controls; no statistically significant difference was observed among the survival group、the death group and the control group; no statistically significant difference was observed among the mild sepsis group, severe sepsis group and control group.
2. PAF-AH gene of Val279Phe polymorphism could have three kinds of genotypes:All 66 patients in the sepsis group were the homozygous Val/Val type; control group 68 cases, only one case was homozygous Phe/Phe type, and the others were homozygous Val/Val type, not found heterozygous Val/Phe type. The Val279Phe genotypic distribution and allele gene frequency in the patients with sepsis was not significantly different from those in the healthy controls; no statistically significant difference was observed among the survival group、the death group and the control group; no statistically significant difference was observed among the mild sepsis group, severe sepsis group and control group.
Conclusion:
No associations were found between PAF-AH gene Val379Ala and Val279Phe polymorphisms and sepsis susceptibility, prognosis and severity.
引文
[1]Levy MM, Fink MP, Marshall JC,et al.2001SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Conference [J].Crit Care Med,2003,31(4):1250-1256.
[2]Bone RC, Balk RA, Cerra FB,et al.Definitions for sepsis and organ f ailure and guidelines for the use of innovative therapies in sepsis.The A CCP/SCCM Consensus Conference Commitee.American College of Chest of Critical Care Medicine[J].Chest,1992,101:1644-1655.
[3]Benveniste J, Boullet C, Brink C, et al. The actions of pasf-acether PAF onguinea-pig isolated heart preparations [J]. J pharmarcology,1983, 80:81-83
[4]Auchampach JA,Pieper GM,Cavero I,et al.Effect of PAF antagonist RP 59227 on myocardical ischemia perfusion injury and neutrophil functi on [J].Basic Res Cadiol,1998,93(5):361-371.
[5]Tjoelker H, Ofbauer LW, Stafforini DM,et al.Platelet-activating factor acet ylhydrolases in health and disease [J].Biochim Biophys Acta.2000,1488: 102-123
[6]Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF a cetylhydrolase activity is associated with post-injury multiple organ failure [J]. Shock,1997,7:170-174
[7]Lopez Diez F, Nieto ML, Fernandez Gallardo S, Gijon MA, Sanchez Crespo M.Occupancy of platelet receptors for platelet-activating factor in patients with septicemia [J].J Clin Invest,1989,83:1733-1740.
[8]Heuer HO. Involvement of platelet-activating factor (PAF) in septic sh ock and priming as indicated by the effect of hetrazepinoic PAF antago nists [J]. Lipids,1991,26:1369-1373.
[9]Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R. Platele t-activating factor (PAF) in experimental and clinical sepsis[J]. Shock,1 997,7:391-404.
[10]Tetta C, Mariano F, Buades J, Ronco C, Wratten ML, Camussi G. Relevance of platelet-activating factor in inflammation and sepsis:mecha nisms and kinetics of removal in extracorporeal treatments [J]. Am J Ki dney Dis,1997,30:S57-65.
[11]Zimmerman GA, McIntyre TM. PAF, ceramide and pulmonary edema: alveolar flooding and a flood of questions [J].Trends Mol Med,2004, 10:245-248
[12]Stafforini, DM.,.McIntyre TM,.Zimmerman GA, Prescott SM. Platelet-activa ting factor acetylhydrolases [J]. J Biol Chem,1997,272:17895-17898.
[13]Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G,Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase [J]. Nature,1995,374:549-553.
[14]Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al.Platelet activating factor acetylhydrolase deficiency.A missense mutati on near the activesite of an anti-inflammatory phospholipase [J]. J Clin Invest, 1996,97:2784-2791.
[15]Yamada Y, Stafforini DM, Imaizumi T, Zimmerman GA, McIntyre TM, Pr escott SM.Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes [J].Proc Natl Acad Sci USA.,1994,91(22):10320-10324.
[16]Jong D Kim, Craig J Baker, Randall F, et al. Platelet activating factor ace tylhydrolase decreases lung reperfusion injury [J].Ann Thorac Surg,2000,70(2): 423-428
[17]Karasawa K.Clinical aspects of plasma platelet-activating factor acetylhydrol ase [J].Biochimica et Biophysica Acta 2006,1761:1359-1372
[18]Gomes RN, Bozza FA, Amancio RT et al. Exogenous platelet-activating fa ctor acetylhydrolase reduces mortality in mice with systemic inflammatoryrespo nse syndrome and sepsis [J]. Shock,2006,26,41-49.
[19]Graham RM, Stephens C J, et al. Plasma degradation of platelet-acti vating factor in severely ill patients with clinical sepsis [J]. Crit Care Med,1994 Feb,22(2):204-12.
[20]Claus RA, Russwurm S, et al. Plasma platelet-activating factor acetylhydro lase activity in critically ill patients [J]. Critical Care Medicine,2005,33,141 6-1419.
[21]Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Corre lation between deficiency of serum PAF acetylhydrolase and respiratory sympto ms in asthmatic children [J].J Clin Invest,1988,82:1983-1991.
[22]Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 —> T missense in exon 9 of the plasma platelet-activating factor acetylhydrola se gene as an independent risk factor for coronary artery disease in Japanese men[J].Metabolism,1998,47:177-181.
[23]Kruse, S, Mao, XQ, Heinzmann A, Blattmann, et al. The Ile198Thr and A la379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma [J].Am. J. Hum. Genet,2000,66:15-22-1530.
[24]S Li, L Stuart, et al. Inter-individual variability of plasma PAF-acety lhydrolase activity in ARDS patients and PAF-AH genotype [J]. Journal of Clinical Pharmacy and Therapeutics,2009,34:447-455
[25]PY LIU,YH LI, HL WU, et al. Platelet-activating factor-acetylhydrolase A 379V (exonll) gene polymorphism is an independent and functional risk factor for premature myocardial infarction[J]. J Thromb Haemost,2006; 4:1023-10 28.
[26]Ewa Ninio, David Tregouet, Jean-Luc Carrier, et al.Platelet-activating fact or acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardi ovascular event in patients with coronary artery disease [J]. Human Molecular Genetics,2004,13:1341-1351.
[27]Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between th e Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe [J]. Atherosclerosis,2 003,168(2):283-288.
[28]Yangsoo Jang, Oh Yoen Kim, Soo Jeong Koh, et al.The Val279Phe Varia nt of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Ca talytic Activities and Cardiovascular Disease in Korean Men [J]. J Clinical En docrinology & Metabolism,2006,91(9):3521-3527
[29]李海林,程飞,黄永坤.血小板活化因子乙酰水解酶基因多态性与支气管哮喘的相关性[J].实用儿科临床杂志,2006,21(20)：1396-1397.
[30]Yamada Y, Yokota M.Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281→Arg mutation [J].Biochem Biophys Re s Commun,1997,236:772-775.
[31]Karasawa K, Harada A, Satoh N, Inoue K, Setaka M.Plasma platelet activating factor-acetylhydrolase (PAF-AH) [J]. Prog Lipid Res,2003,42:93-114.
[32]Hiramoto MD, Hidemi Yoshida H, Imaizumi T, et al.A mutation in Platelet-activating factor acetylhydrolase (Val2792Phe) is a genetic risk for stroke[J]. Stroke,1997,28:2417-2420
[33]T Minami, H Suzuki, T Takeuchi, S Uemura, J Sugatani,et al.A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease [J]. J Pediatr,2005;147(1):78-83.
[34]Ping Fan, Hong Wei Liu, Xiao Su Wang,et al.Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome[J].Hum Reprod,2010,25: 1288-1294.
[35]Satoh N, Asano K, Naoki K, et al. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma[J].Am J Respir Crit Care Med,1999,159:974-979.
[36]Yoshiji Yamada, Sahoko Ichihara, Hideo Izawa,et al. Association of a G994T (Val279Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy [J]. J Hum Genet,2001,46:436-441.
[37]周春,经承学,李铭芳,谢湘芝.血小板活化因子水解酶基因突变与原发性肾病综合征的相关性[J].实用儿科临床杂志,2007,22(23)：1814-1816.
[38]张惠平,孙福成,王抒,等.血小板活化因子乙酰水解酶基因V279F变异与冠心病的关系[J].中华老年医学杂志,2006,25(12)：895-899.
[39]张雄,袁成林.血小板活化因子乙酰水解酶基因994G→T突变与脑梗塞的关联 性[J].中国医学遗传学杂志,2005,4(22)：450-452
[40]林大东,毕新岭,朱克军,等.血小板活化因子乙酰水解酶基因Val279Phe突变与银屑病的相关性研究[J].中华皮肤科杂志,2005,38(3)：151-153.
[1]Tjoelker H,Ofbauer LW,Stafforini DM,et al.Platelet-activating factor acetyl hydrolases in health and disease [J].Biochim Biophys Acta.2000,1488:10 2-123
[2]Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF a cetylhydrolase activity is associated with post-injury multiple organ failure [J]. Shock,1997,7:170-174
[3]Snyder F, Lee TC, Blank M, Malone B, Woodard D, Robinson M. Platelet-activating factor:alternate pathways of biosynthesis, mechanism of inactivation, and reacylation of lyso-PAF with arachidonate[J]. Adv Prostaglandin Thrombo xaneLeukot Res,1985,15:693-696.
[4]Murakami M, Kudo I. Phospholipase A2 [J] J Biochem,2002,131:285-292
[5]Hattori K, Adachi H, Matsuzawa A, et al. PAF Acetylhydrolase [J].J Biol Chem,1996,271:33032-33038.
[6]Hiramoto MD, Hidemi Yoshida H, Imaizumi T, et al.A mutation in Plat elet-activating factor acetylhydrolase (Val2792Phe) is a genetic risk for stroke [J]. Stroke,1997,28:2417-2420
[7]Stafforini DM.,McIntyre TM,Zimmerman GA,Prescott SM. Platelet-activating factor acetylhydrolases[J]. J.Biol. Chem.1997,272:17895-17898.
[8]Narahara H, Nishioka Y, Johnston JM. Secretion of platelet-activating factor acetylhydrolase by human decidual macrophages[J]. J Clin Endocrinol Metab, 1993,77:1258-1262.
[9]Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M,et al. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating fa ctor[J]. J Biol Chem,1997,272:19708-19713.
[10]Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M,et al. Cell ular source(s) of platelet-activating-factor acetylhydrolase activity in plasma [J]. Biochem Biophys Res Commun,1999,261:511-514
[11]Guerra R,Zhao B,Mooser V,et al. Determinants of plasma platelet-activa ting factor acetylhydrolase:heritability and relationship to plasma lipoproteins [J]. J Lipid Res,1997,38:2281-2288
[12]Graham RM, Stephens CJ, Silvester W, et al.Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis [J]. Crit CareMed, 1994,22:204-212.
[13]Morgan EN, Boyle EM Jr, Yun W, et al. Platelet-activating factor acetylhy drolase prevents myocardial ischemia-reperfusion injury [J].Circulation,1999,10 0:365-368.
[14]Claus RA, Russwurm S, Dohrn B, Bauer M, Losche W 2005. Plasma plat elet-activating factor acetylhydrolase activity in critically ill patients[J]. Crit Car e Med,2005,33(6):1462-1463.
[15]Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G,Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase [J]. Nature,1995,374:549-553.
[16]Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H et al.Platelet-activating factor acetylhydrolase deficiency. A missense mutati on near the activesite of an anti-inflammatory phospholipase[J]. J Clin Invest,1 996,97:2784-2791.
[17]Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Corre lation between deficiency of serum PAF acetylhydrolase and respiratory sympto ms in asthmatic children[J]. J Clin Invest,1988,82:1983-1991.
[18]Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C,et al. Evidence for t he existence of the PAF acetylhydrolase mutation(Val279Phe)in non-Japanese p opulations:a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan[J]. Thro mb Res,2001,101:231-234.
[19]Kruse, S., Mao, X.Q., Heinzmann, A., Blattmann, S., Roberts, M.H.,Braun, S., Gao, P.S., Forster, J., Kuehr, J., Hopkin, J.M. et al.The Ile198Thr and Al a379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities a nd are associated with atopy and asthma[J].Am. J. Hum. Genet,2000,66:1522-1530.
[20]Karasawa K, Harada A, Satoh N, Inoue K, Setaka MP,et al.Plasma platelet activating factor-acetylhydrolase (PAF-AH) [J]. Prog Lipid Res,2003,42:93-114.
[21]Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 —> T missense in exon 9 of the plasma platelet-activating factor acetylhydrola se gene as an independent risk factor for coronary artery disease in Japanese men[J]. Metabolism,1998,47:177-181.
[22]Satoh N, Asano K, Naoki K, et al. Plasma platelet-activating factor acetylh ydrolase deficiency in Japanese patients with asthma [J].Am J Respir Crit Ca re Med,1999,159:974-979.
[23]王振华,赵凯珠,等.哮喘患儿血小板活化因子乙酰水解酶活性的研究[J].实用儿科临床杂志,2004,2(19)：120-121
[24]王振华,赵凯珠,等.血小板活化因子乙酰水解酶基因多态性活性与儿童哮喘易感性关系的研究[J].中国实用儿科杂志,2004,3(19)：159-161
[25]张雄,袁成林.血小板活化因子乙酰水解酶基因994G→T突变与脑梗塞的关联性[J].中国医学遗传学杂志,2005,4(22)：450-452
[26]张淑云,李江,等.血小板活化因子乙酰水解酶基因突变Val279-Phe与急性脑出血的相关性研究[J].神经精神疾病杂志,2003,2(3)：112-114
[27]Jong D Kim, Craig J Baker, Randall F, et al. Platelet activating factor acet ylhydrolase decreases lung reperfusion injury [J].Ann Thorac Surg,2000,70(2): 423-428
[28]William R. Henderson, Jr., Jiangyang Lu, Karen M.,et al. Recombinant Hu man Platelet-Activating Factor-Acetylhydrolase Inhibits Airway Inflammation a nd Hyperreactivity in Mouse Asthma Model[J]. J Immunol,2000,164(6):3360-3367
[2]Bone RC, Balk RA, Cerra FB,et al.Definitions for sepsis and organ f ailure and guidelines for the use of innovative therapies in sepsis.The A CCP/SCCM Consensus Conference Commitee.American College of Chest of Critical Care Medicine[J].Chest,1992,101:1644-1655.
[3]Benveniste J, Boullet C, Brink C, et al. The actions of pasf-acether PAF onguinea-pig isolated heart preparations [J]. J pharmarcology,1983, 80:81-83
[4]Auchampach JA,Pieper GM,Cavero I,et al.Effect of PAF antagonist RP 59227 on myocardical ischemia perfusion injury and neutrophil functi on [J].Basic Res Cadiol,1998,93(5):361-371.
[5]Tjoelker H, Ofbauer LW, Stafforini DM,et al.Platelet-activating factor acet ylhydrolases in health and disease [J].Biochim Biophys Acta.2000,1488: 102-123
[6]Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF a cetylhydrolase activity is associated with post-injury multiple organ failure [J]. Shock,1997,7:170-174
[7]Lopez Diez F, Nieto ML, Fernandez Gallardo S, Gijon MA, Sanchez Crespo M.Occupancy of platelet receptors for platelet-activating factor in patients with septicemia [J].J Clin Invest,1989,83:1733-1740.
[8]Heuer HO. Involvement of platelet-activating factor (PAF) in septic sh ock and priming as indicated by the effect of hetrazepinoic PAF antago nists [J]. Lipids,1991,26:1369-1373.
[9]Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Rabinovici R. Platele t-activating factor (PAF) in experimental and clinical sepsis[J]. Shock,1 997,7:391-404.
[10]Tetta C, Mariano F, Buades J, Ronco C, Wratten ML, Camussi G. Relevance of platelet-activating factor in inflammation and sepsis:mecha nisms and kinetics of removal in extracorporeal treatments [J]. Am J Ki dney Dis,1997,30:S57-65.
[11]Zimmerman GA, McIntyre TM. PAF, ceramide and pulmonary edema: alveolar flooding and a flood of questions [J].Trends Mol Med,2004, 10:245-248
[12]Stafforini, DM.,.McIntyre TM,.Zimmerman GA, Prescott SM. Platelet-activa ting factor acetylhydrolases [J]. J Biol Chem,1997,272:17895-17898.
[13]Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G,Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase [J]. Nature,1995,374:549-553.
[14]Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, et al.Platelet activating factor acetylhydrolase deficiency.A missense mutati on near the activesite of an anti-inflammatory phospholipase [J]. J Clin Invest, 1996,97:2784-2791.
[15]Yamada Y, Stafforini DM, Imaizumi T, Zimmerman GA, McIntyre TM, Pr escott SM.Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes [J].Proc Natl Acad Sci USA.,1994,91(22):10320-10324.
[16]Jong D Kim, Craig J Baker, Randall F, et al. Platelet activating factor ace tylhydrolase decreases lung reperfusion injury [J].Ann Thorac Surg,2000,70(2): 423-428
[17]Karasawa K.Clinical aspects of plasma platelet-activating factor acetylhydrol ase [J].Biochimica et Biophysica Acta 2006,1761:1359-1372
[18]Gomes RN, Bozza FA, Amancio RT et al. Exogenous platelet-activating fa ctor acetylhydrolase reduces mortality in mice with systemic inflammatoryrespo nse syndrome and sepsis [J]. Shock,2006,26,41-49.
[19]Graham RM, Stephens C J, et al. Plasma degradation of platelet-acti vating factor in severely ill patients with clinical sepsis [J]. Crit Care Med,1994 Feb,22(2):204-12.
[20]Claus RA, Russwurm S, et al. Plasma platelet-activating factor acetylhydro lase activity in critically ill patients [J]. Critical Care Medicine,2005,33,141 6-1419.
[21]Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Corre lation between deficiency of serum PAF acetylhydrolase and respiratory sympto ms in asthmatic children [J].J Clin Invest,1988,82:1983-1991.
[22]Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 —> T missense in exon 9 of the plasma platelet-activating factor acetylhydrola se gene as an independent risk factor for coronary artery disease in Japanese men[J].Metabolism,1998,47:177-181.
[23]Kruse, S, Mao, XQ, Heinzmann A, Blattmann, et al. The Ile198Thr and A la379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma [J].Am. J. Hum. Genet,2000,66:15-22-1530.
[24]S Li, L Stuart, et al. Inter-individual variability of plasma PAF-acety lhydrolase activity in ARDS patients and PAF-AH genotype [J]. Journal of Clinical Pharmacy and Therapeutics,2009,34:447-455
[25]PY LIU,YH LI, HL WU, et al. Platelet-activating factor-acetylhydrolase A 379V (exonll) gene polymorphism is an independent and functional risk factor for premature myocardial infarction[J]. J Thromb Haemost,2006; 4:1023-10 28.
[26]Ewa Ninio, David Tregouet, Jean-Luc Carrier, et al.Platelet-activating fact or acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardi ovascular event in patients with coronary artery disease [J]. Human Molecular Genetics,2004,13:1341-1351.
[27]Abuzeid AM, Hawe E, Humphries SE, Talmud PJ. Association between th e Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe [J]. Atherosclerosis,2 003,168(2):283-288.
[28]Yangsoo Jang, Oh Yoen Kim, Soo Jeong Koh, et al.The Val279Phe Varia nt of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Ca talytic Activities and Cardiovascular Disease in Korean Men [J]. J Clinical En docrinology & Metabolism,2006,91(9):3521-3527
[29]李海林,程飞,黄永坤.血小板活化因子乙酰水解酶基因多态性与支气管哮喘的相关性[J].实用儿科临床杂志,2006,21(20)：1396-1397.
[30]Yamada Y, Yokota M.Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281→Arg mutation [J].Biochem Biophys Re s Commun,1997,236:772-775.
[31]Karasawa K, Harada A, Satoh N, Inoue K, Setaka M.Plasma platelet activating factor-acetylhydrolase (PAF-AH) [J]. Prog Lipid Res,2003,42:93-114.
[32]Hiramoto MD, Hidemi Yoshida H, Imaizumi T, et al.A mutation in Platelet-activating factor acetylhydrolase (Val2792Phe) is a genetic risk for stroke[J]. Stroke,1997,28:2417-2420
[33]T Minami, H Suzuki, T Takeuchi, S Uemura, J Sugatani,et al.A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease [J]. J Pediatr,2005;147(1):78-83.
[34]Ping Fan, Hong Wei Liu, Xiao Su Wang,et al.Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome[J].Hum Reprod,2010,25: 1288-1294.
[35]Satoh N, Asano K, Naoki K, et al. Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma[J].Am J Respir Crit Care Med,1999,159:974-979.
[36]Yoshiji Yamada, Sahoko Ichihara, Hideo Izawa,et al. Association of a G994T (Val279Phe) polymorphism of the plasma platelet-activating factor acetylhydrolase gene with myocardial damage in Japanese patients with nonfamilial hypertrophic cardiomyopathy [J]. J Hum Genet,2001,46:436-441.
[37]周春,经承学,李铭芳,谢湘芝.血小板活化因子水解酶基因突变与原发性肾病综合征的相关性[J].实用儿科临床杂志,2007,22(23)：1814-1816.
[38]张惠平,孙福成,王抒,等.血小板活化因子乙酰水解酶基因V279F变异与冠心病的关系[J].中华老年医学杂志,2006,25(12)：895-899.
[39]张雄,袁成林.血小板活化因子乙酰水解酶基因994G→T突变与脑梗塞的关联 性[J].中国医学遗传学杂志,2005,4(22)：450-452
[40]林大东,毕新岭,朱克军,等.血小板活化因子乙酰水解酶基因Val279Phe突变与银屑病的相关性研究[J].中华皮肤科杂志,2005,38(3)：151-153.
[1]Tjoelker H,Ofbauer LW,Stafforini DM,et al.Platelet-activating factor acetyl hydrolases in health and disease [J].Biochim Biophys Acta.2000,1488:10 2-123
[2]Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC. Reduced PAF a cetylhydrolase activity is associated with post-injury multiple organ failure [J]. Shock,1997,7:170-174
[3]Snyder F, Lee TC, Blank M, Malone B, Woodard D, Robinson M. Platelet-activating factor:alternate pathways of biosynthesis, mechanism of inactivation, and reacylation of lyso-PAF with arachidonate[J]. Adv Prostaglandin Thrombo xaneLeukot Res,1985,15:693-696.
[4]Murakami M, Kudo I. Phospholipase A2 [J] J Biochem,2002,131:285-292
[5]Hattori K, Adachi H, Matsuzawa A, et al. PAF Acetylhydrolase [J].J Biol Chem,1996,271:33032-33038.
[6]Hiramoto MD, Hidemi Yoshida H, Imaizumi T, et al.A mutation in Plat elet-activating factor acetylhydrolase (Val2792Phe) is a genetic risk for stroke [J]. Stroke,1997,28:2417-2420
[7]Stafforini DM.,McIntyre TM,Zimmerman GA,Prescott SM. Platelet-activating factor acetylhydrolases[J]. J.Biol. Chem.1997,272:17895-17898.
[8]Narahara H, Nishioka Y, Johnston JM. Secretion of platelet-activating factor acetylhydrolase by human decidual macrophages[J]. J Clin Endocrinol Metab, 1993,77:1258-1262.
[9]Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M,et al. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating fa ctor[J]. J Biol Chem,1997,272:19708-19713.
[10]Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M,et al. Cell ular source(s) of platelet-activating-factor acetylhydrolase activity in plasma [J]. Biochem Biophys Res Commun,1999,261:511-514
[11]Guerra R,Zhao B,Mooser V,et al. Determinants of plasma platelet-activa ting factor acetylhydrolase:heritability and relationship to plasma lipoproteins [J]. J Lipid Res,1997,38:2281-2288
[12]Graham RM, Stephens CJ, Silvester W, et al.Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis [J]. Crit CareMed, 1994,22:204-212.
[13]Morgan EN, Boyle EM Jr, Yun W, et al. Platelet-activating factor acetylhy drolase prevents myocardial ischemia-reperfusion injury [J].Circulation,1999,10 0:365-368.
[14]Claus RA, Russwurm S, Dohrn B, Bauer M, Losche W 2005. Plasma plat elet-activating factor acetylhydrolase activity in critically ill patients[J]. Crit Car e Med,2005,33(6):1462-1463.
[15]Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G,Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase [J]. Nature,1995,374:549-553.
[16]Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H et al.Platelet-activating factor acetylhydrolase deficiency. A missense mutati on near the activesite of an anti-inflammatory phospholipase[J]. J Clin Invest,1 996,97:2784-2791.
[17]Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Corre lation between deficiency of serum PAF acetylhydrolase and respiratory sympto ms in asthmatic children[J]. J Clin Invest,1988,82:1983-1991.
[18]Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C,et al. Evidence for t he existence of the PAF acetylhydrolase mutation(Val279Phe)in non-Japanese p opulations:a preliminary study in Turkey, Azerbaijan, and Kyrgyzstan[J]. Thro mb Res,2001,101:231-234.
[19]Kruse, S., Mao, X.Q., Heinzmann, A., Blattmann, S., Roberts, M.H.,Braun, S., Gao, P.S., Forster, J., Kuehr, J., Hopkin, J.M. et al.The Ile198Thr and Al a379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities a nd are associated with atopy and asthma[J].Am. J. Hum. Genet,2000,66:1522-1530.
[20]Karasawa K, Harada A, Satoh N, Inoue K, Setaka MP,et al.Plasma platelet activating factor-acetylhydrolase (PAF-AH) [J]. Prog Lipid Res,2003,42:93-114.
[21]Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 —> T missense in exon 9 of the plasma platelet-activating factor acetylhydrola se gene as an independent risk factor for coronary artery disease in Japanese men[J]. Metabolism,1998,47:177-181.
[22]Satoh N, Asano K, Naoki K, et al. Plasma platelet-activating factor acetylh ydrolase deficiency in Japanese patients with asthma [J].Am J Respir Crit Ca re Med,1999,159:974-979.
[23]王振华,赵凯珠,等.哮喘患儿血小板活化因子乙酰水解酶活性的研究[J].实用儿科临床杂志,2004,2(19)：120-121
[24]王振华,赵凯珠,等.血小板活化因子乙酰水解酶基因多态性活性与儿童哮喘易感性关系的研究[J].中国实用儿科杂志,2004,3(19)：159-161
[25]张雄,袁成林.血小板活化因子乙酰水解酶基因994G→T突变与脑梗塞的关联性[J].中国医学遗传学杂志,2005,4(22)：450-452
[26]张淑云,李江,等.血小板活化因子乙酰水解酶基因突变Val279-Phe与急性脑出血的相关性研究[J].神经精神疾病杂志,2003,2(3)：112-114
[27]Jong D Kim, Craig J Baker, Randall F, et al. Platelet activating factor acet ylhydrolase decreases lung reperfusion injury [J].Ann Thorac Surg,2000,70(2): 423-428
[28]William R. Henderson, Jr., Jiangyang Lu, Karen M.,et al. Recombinant Hu man Platelet-Activating Factor-Acetylhydrolase Inhibits Airway Inflammation a nd Hyperreactivity in Mouse Asthma Model[J]. J Immunol,2000,164(6):3360-3367